發(fā)布時(shí)間：2018-06-03 18:10

  本文選題：精神分裂癥 + 慢性乙型病毒性肝炎��； 參考：《中國(guó)新藥雜志》2017年01期

【摘要】：目的:比較奧氮平和利培酮治療精神分裂癥合并慢性乙型病毒性肝炎(慢性乙肝)患者的療效及其對(duì)糖脂代謝的影響。方法:將合并慢性乙肝的65例精神分裂癥患者分為奧氮平組(n=32)和利培酮組(n=33),治療8周。在治療前及治療后8周末采用陽(yáng)性與陰性癥狀量表(PANSS)進(jìn)行評(píng)分,評(píng)定療效;比較2組治療前后血糖、血脂變化和體質(zhì)量改變。結(jié)果:奧氮平組和利培酮組治療8周后PANSS減分率分別為65.6%和66.7%,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。奧氮平組患者治療后體質(zhì)量指數(shù)(BMI)、空腹血糖、甘油三酯、總膽固醇和低密度脂蛋白升高。利培酮組患者治療后空腹血糖、總膽固醇升高,但幅度低于奧氮平組。結(jié)論:利培酮治療合并慢性乙肝的精神分裂癥患者的療效與奧氮平相當(dāng),但對(duì)糖脂代謝和BMI影響較小,較適于合并慢性乙肝精神分裂癥患者的治療。
[Abstract]:Aim: to compare the efficacy of olanzapine and risperidone in the treatment of schizophrenia with chronic hepatitis B (CHB) and its effect on glucose and lipid metabolism. Methods: 65 schizophrenic patients with chronic hepatitis B were divided into olanzapine group (n = 32) and risperidone group (n = 33) for 8 weeks. Positive and negative symptom scale (PANSS) was used to evaluate the efficacy before and after treatment, and the changes of blood glucose, blood lipid and body mass were compared before and after treatment. Results: the PANSS reduction rates of olanzapine group and risperidone group were 65.6% and 66.7% respectively after 8 weeks of treatment with no significant difference (P 0.05). In the olanzapine group, body mass index (BMI), fasting blood glucose, triglyceride, total cholesterol and low density lipoprotein increased after treatment. The fasting blood glucose and total cholesterol in risperidone group were higher than those in olanzapine group. Conclusion: the efficacy of risperidone in the treatment of schizophrenia with chronic hepatitis B is similar to that of olanzapine, but has little effect on glucose and lipid metabolism and BMI, so it is more suitable for the treatment of patients with chronic hepatitis B schizophrenia.
【作者單位】： 北京回龍觀醫(yī)院心身醫(yī)學(xué)科;
【基金】：北京市自然科學(xué)基金青年項(xiàng)目(7154208)
【分類號(hào)】：R749.3;R512.62

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張德亮,孟慶玲;奧氮平致嚴(yán)重低血鉀1例[J];中國(guó)臨床藥學(xué)雜志;2000年05期

2 吳向平,范小琴;超量服奧氮平搶救成功1例[J];上海精神醫(yī)學(xué);2004年05期

3 ;奧氮平和利培酮不宜用于老年癡呆患者[J];藥物不良反應(yīng)雜志;2004年05期

4 趙黎君;韓耀靜;羅烈嵐;;奧氮平與利培酮治療癡呆患者的行為和精神癥狀的對(duì)照研究[J];中國(guó)民康醫(yī)學(xué);2006年05期

5 王德林;孟慶豐;;國(guó)產(chǎn)奧氮平對(duì)腦器質(zhì)性精神障礙的療效分析[J];中國(guó)神經(jīng)免疫學(xué)和神經(jīng)病學(xué)雜志;2008年01期

6 何凡;鄭毅;;奧氮平治療難治性Tourette綜合征1例[J];臨床精神醫(yī)學(xué)雜志;2008年06期

7 毛星;劉洪秋;陳玉輝;;奧氮平與阿立哌唑治療難治性精神分裂癥70例的對(duì)照研究[J];中國(guó)民康醫(yī)學(xué);2010年11期

8 毛星;陳玉輝;劉洪秋;;奧氮平治療難治性精神分裂癥45例的療效分析[J];中國(guó)民康醫(yī)學(xué);2010年13期

9 任季冬;戢彬;蔡旭明;;奧氮平與利培酮治療老年期精神障礙的對(duì)照研究[J];檢驗(yàn)醫(yī)學(xué)與臨床;2010年09期

10 楊雀屏;張恒;包pせ，

本文編號(hào)：1973712